MedTrace Logo

Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00003606 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2021-02-21

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy with or without epirubicin and cyclophosphamide is more effective in treating patients with extensive stage small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without epirubicin and cyclophosphamide in treating patients who have extensive stage small cell lung cancer.

Conditions

Interventions

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

epirubicin hydrochloride

DRUG

etoposide

RADIATION

radiation therapy

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Jean Louis Pujol, MD · Hopital Arnaud de Villeneuve

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-03-31
Primary Completion
1999-10-01
Completion
2001-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003606 on ClinicalTrials.gov